Seite auswählen

The pharmaceutical and medical technology company B. Braun Melsungen has achieved the second best result in the company’s history with a group surplus of 255.7 million Euro (-7.8 percent). The slight decline in earnings was caused, among other things, by start-up costs for new manufacturing plants, increased commodity prices and currency fluctuations. In contrast, the group turnover increased by 4.2 percent to a record 4.61 billion Euro.

The divisions Aesculap (2.16 billion Euro, +3.5 percent) and Hospital Care (1.36 billion Euro, +5.8 percent) contributed the most to the growth in turnover. The Asia/Pacific region continues to drive the group’s growth (+12.2 percent). Further growth of between five and six percent is expected for 2012.

[ilink url=““] link to source (B. Braun)[/ilink]